Home › Compare › WARAF vs MRK

WARAF vs MRK: Dividend Comparison 2026

WARAF yields 710.98% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WARAF wins by $1033603.87M in total portfolio value
10 years
WARAF
WARAF
● Live price
710.98%
Share price
$0.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1033603.90M
Annual income
$809,603,060,551.21
Full WARAF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — WARAF vs MRK

📍 WARAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWARAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WARAF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
WARAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WARAF
Annual income on $10K today (after 15% tax)
$60,433.70/yr
After 10yr DRIP, annual income (after tax)
$688,162,601,468.53/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, WARAF beats the other by $688,162,600,660.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WARAF + MRK for your $10,000?

WARAF: 50%MRK: 50%
100% MRK50/50100% WARAF
Portfolio after 10yr
$516801.97M
Annual income
$404,801,530,750.76/yr
Blended yield
78.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

WARAF
No analyst data
Altman Z
-970.8
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WARAF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWARAFMRK
Forward yield710.98% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$1033603.90M ✓$30.7K
Annual income after 10y$809,603,060,551.21 ✓$950.29
Total dividends collected$1015518.95M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WARAF vs MRK ($10,000, DRIP)

YearWARAF PortfolioWARAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$81,798$71,098.47$11,192$351.54+$70.6K → WARAF
2$631,052$543,527.69$12,524$392.70+$618.5K → WARAF
3$4,594,069$3,918,843.25$14,015$438.65+$4.58M → WARAF
4$31,578,496$26,662,842.02$15,682$489.96+$31.56M → WARAF
5$205,072,910$171,283,919.25$17,547$547.23+$205.06M → WARAF
6$1,258,988,273$1,039,560,259.07$19,632$611.16+$1258.97M → WARAF
7$7,311,689,405$5,964,571,953.50$21,963$682.53+$7311.67M → WARAF
8$40,197,149,254$32,373,641,590.85$24,571$762.18+$40197.12M → WARAF
9$209,346,583,144$166,335,633,441.56$27,486$851.08+$209346.56M → WARAF
10$1,033,603,904,515$809,603,060,551.21$30,745$950.29+$1033603.87M → WARAF

WARAF vs MRK: Complete Analysis 2026

WARAF — Stock

Waraba Gold Limited acquires and evaluates gold properties in Mali, West Africa. Its flagship prospective gold exploration project is the Fokolore project located in West Mali. The company was formerly known as Zenith Exploration Inc. and changed its name to Waraba Gold Limited in October 2020. Waraba Gold Limited was incorporated in 2015 and is headquartered in Vancouver, Canada.

Full WARAF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this WARAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WARAF vs SCHDWARAF vs JEPIWARAF vs OWARAF vs KOWARAF vs MAINWARAF vs JNJWARAF vs ABBVWARAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.